Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q3 2023 Earnings Presentation
8 slides from Sanuwave Health's earnings presentation, Nov 10, 2023
Slide 1: Q3 2023 Update
Q3 2023 Update November 10, 2023
Slide 2: Live Presentation and Dial-in Information
Live Presentation Friday, November 10, 2023, 8:00 AM (ET) Participant Dial-in Information Toll Free: 1-877-407-0784 Toll/International: 1-201-689-8560 OR click the Call me™ link for instant telephone access to the event. https://callme.viavid.com/viavid/?callme=true&passcode=13732361&h=true&info=com
Slide 3: Forward Looking Statements
3 Forward Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the Company’s current views with respect to certain current and future events and financial performance. Forward-looking sta
Slide 4: Company Financials Q3 2023
4 Company Financials Q3 2023 Consistent topline growth while managing operating costs. (in millions) Q3 2023 Q3 2022 YoY Revenue $5.0 $4.2 + 19% Gross Profit $3.5 $3.0 + 17% Gross Margin 71% 72% -100bp Operating $4.1 $5.5 -25% Expense Revenue Gross Profit Operating L o s s Operating Loss ($0.5) ($2.
Slide 5: Improved operational profitability
5 Improved operational profitability (in millions) Q3 2023 Q3 2022 Net (Loss) Income ($23.7) ($1.1) Non-GAAP adjustments: Interest Expense 3.8 3.8 Depreciation and Amortization 0.3 0.2 EBITDA ($19.6) $2.9 Change in fair value of derivative liabilities 19.3 (5.2) Loss on extinguishment of debt - 0.1
Slide 6: Growing UltraMist Systems & Consumables Sales
6 Growing UltraMist Systems & Consumables Sales Consumable Revenue UM System Sales + 24% yoy 60 • 581 Active Systems in the 3.5 +11% seq 55 field at end Q3* 3 49 50 • 55 systems were sold in 2.5 Q3 2023 (28 in Q1 2023 40 and 49 in Q2) 2 28 • 24% increase in 30 1.5 consumables revenue. $3.1 million i
Slide 7: 2023 Q4 Revenue Guidance
7 2023 Q4 Revenue Guidance 4th Quarter 2023 Revenue estimate: +15 – 25% vs Q4 2022 Estimated Business Model Break Even Gross Margin Opex $1.8mm/mo 75% $1.4mm/mo Unbounded Upside: 1% market share in US wound market = $450 million
Slide 8: Summary
8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for Patients, Payors, and Providers. SANUWAVE is in a prime position to benefit: § Approved products protected by strong IP § Strong existing reimbursement with room to impr